Stockscreener 앱 받기
53.24
4.00%
-2.22
시장 영업 전:
53.24
Biomarin Pharmaceutical Inc 주식(BMRN)의 최신 뉴스
BioMarin Q1 Earnings Miss, Sales Beat, '26 Revenue Guidance Raised - sharewise.com
BioMarin (NASDAQ: BMRN) Q1 profit drops as $4.8B Amicus acquisition ramps - Stock Titan
BioMarin Pharmaceutical Q1 Revenue Beat Backed by Voxzogo Strength, Diversified Portfolio, Wedbush Says - marketscreener.com
BioMarin Enters 'Transition Year' as Enzyme Portfolio Expands After Amicus Deal, Morgan Stanley Says - marketscreener.com
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Q1 2026 Earnings Call Transcript - Insider Monkey
BioMarin Pharmaceutical Q1 2026: $0.76 EPS Falls Short — Deep Dive - AlphaStreet
Bernstein SocGen lowers BioMarin stock price target on guidance update By Investing.com - Investing.com Canada
MSN Money - MSN
Evercore ISI raises BioMarin stock price target on valuation gap - Investing.com
Evercore ISI raises BioMarin stock price target on valuation gap By Investing.com - Investing.com UK
BMRN Q1 Deep Dive: Amicus Acquisition, Pipeline Milestones, and Order Dynamics Shape Outlook - TradingView
BioMarin Boosts 2026 Outlook After Amicus Deal - TipRanks
BioMarin Q1 2026 Earnings Preview: Revenue Growth Expected to SlowNews and Statistics - IndexBox
BioMarin Pharmaceutical Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
Compared to Estimates, BioMarin (BMRN) Q1 Earnings: A Look at Key Metrics - Yahoo Finance
BioMarin (BMRN) Q1 2026 Earnings Transcript - AOL.com
BMRN: Amicus acquisition drives 20% 2026 revenue growth outlook and portfolio expansion - TradingView
BioMarin Q1 2026 slides: revenue beats forecast, eyes 20% growth - Investing.com
BioMarin Pharmaceutical Q1 Earnings Call Highlights - Yahoo Finance
Earnings call transcript: BioMarin Q1 2026 beats EPS forecasts, stock dips slightly - Investing.com
Transcript: Biomarin Pharmaceutical Q1 2026 Earnings Conference Call - Benzinga
BioMarin Pharmaceutical (BMRN) Q1 Earnings Lag Estimates - Yahoo Finance
BioMarin Pharmaceutical Inc. 2026 Q1ResultsEarnings Call Presentation (NASDAQ:BMRN) 2026-05-04 - Seeking Alpha
BioMarin Pharmaceutical Inc (NASDAQ:BMRN) Q1 Earnings Miss Masked by Raised 2026 Guidance - ChartMill
BioMarin Pharmaceutical Q1 Non-GAAP Earnings Fall, Revenue Rises; 2026 Guidance Revised - marketscreener.com
Earnings Flash (BMRN) BioMarin Pharmaceutical Inc. Reports Q1 Revenue $766.2M, vs. FactSet Est of $752.2M - marketscreener.com
BioMarin beats estimates, raises guidance on Amicus deal By Investing.com - Investing.com Nigeria
(BMRN) BioMarin Pharmaceutical Expects Full Year 2026 Revenue Range $3.83B$3.93B - marketscreener.com
BioMarin beats estimates, raises guidance on Amicus deal - Investing.com
BioMarin: Q1 Earnings Snapshot - marketscreener.com
Earnings Flash (BMRN) BioMarin Pharmaceutical Inc. Posts Q1 Adjusted EPS $0.76 per Share, vs. FactSet Est of $0.91 - marketscreener.com
BioMarin Pharmaceutical (NASDAQ:BMRN) Misses Q1 CY2026 Revenue Estimates - Yahoo Finance
BioMarin (NASDAQ: BMRN) raises 2026 sales view following Amicus deal - Stock Titan
BioMarin Pharmaceutical Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
BioMarin Reports First Quarter 2026 Financial and Operating Results - Santa Maria Times
Mucopolysaccharidoses Market to Reach USD 4,389.85 Million - openPR.com
BioMarin Pharmaceutical (BMRN) Reports Earnings Tomorrow: What To Expect - Yahoo Finance
BioMarin Pharmaceutical Q1 2026 earnings preview - MSN
BioMarin Presents New Data on the Effect of Long-Term Treatment with VOXZOGO® (vosoritide) on Arm Span, Bone Health and Growth in Children With Achondroplasia at the Pediatric Endocrine Society's 2026 Annual Meeting - The AI Journal
Biomarin presents new data on the effect of long-term treatment with Voxzogo® (vosoritide) on arm span, bone health and growth in children with achondroplasia - marketscreener.com
Six-year study finds bone health maintained in children on VOXZOGO - Stock Titan
Assessing BioMarin (BMRN) Valuation As Shares Show Recent Weakness And DCF Signals Deep Discount - Sahm
BioMarin acquires Amicus Therapeutics for $4.8bn - MSN
BioMarin Pharmaceutical Inc expected to post earnings of 79 cents a shareEarnings Preview - TradingView
BioMarin Amicus Deal Expands Rare Disease Reach And Adds Kidney Asset - Sahm
How Will BioMarin Pharmaceutical Stock React To Its Upcoming Earnings? - Trefis
BIOMARIN SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Reminds Investors with Losses in Excess Of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against BioMarin Pharmaceutical Inc.BM - TMX Newsfile
Short Interest in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Rises By 14.9% - MarketBeat
BMRN News | BIOMARIN PHARMACEUTICAL INC (NASDAQ:BMRN) - ChartMill
Precision Trading with Biomarin Pharmaceutical Inc. (BMRN) Risk Zones - Stock Traders Daily
BioMarin Closes Amicus Deal As FOLD Delists And Indices Adjust - Sahm
BioMarin Pharmaceutical Earnings Notes - Trefis
Vanguard reports 5.25% stake in BioMarin (NASDAQ: BMRN) - Stock Titan
BioMarin Pharmaceutical (BMRN) Projected to Post Quarterly Earnings on Monday - MarketBeat
Pictet Asset Management Holding SA Raises Stake in BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
BioMarin closes $4.8B Amicus deal to boost rare disease portfolio - MSN
Amicus Therapeutics (NASDAQ: FOLD) director’s shares and options cashed out in BioMarin deal - Stock Titan
Amicus Therapeutics (FOLD) director cashes out stock and options in BioMarin deal - Stock Titan
BioMarin deal pays Amicus (NASDAQ: FOLD) director $14.50 per share - Stock Titan
Amicus Therapeutics (NASDAQ: FOLD) director cashes out equity in BioMarin deal - Stock Titan
Amicus Therapeutics (NASDAQ: FOLD) director equity paid out at $14.50 in BioMarin deal - Stock Titan
Director at Amicus (NASDAQ: FOLD) exits stake in BioMarin deal - Stock Titan
BioMarin-Amicus deal pays out Amicus (NASDAQ: FOLD) director - Stock Titan
BioMarin acquisition cashes out Amicus (FOLD) director’s shares and options - Stock Titan
Amicus Therapeutics (FOLD) CAO exits stock and options in BioMarin deal - Stock Titan
0.14%
0.48%
자본화:
|
볼륨(24시간):